Group 1 - The core announcement is that Brainstorm Cell Therapeutics has completed a share placement and a rights offering, raising approximately HKD 500.68 million for various strategic purposes [1] - The share placement involved the issuance of 92 million shares at HKD 5.6 per share to at least six independent third-party subscribers, completed on January 27 [1] - The rights offering, which also involved the issuance of 92 million new shares at the same price, was completed on February 5 [1] Group 2 - Following the transactions, the total number of shares for Brainstorm increased from 1.266278 billion to 1.358278 billion [1] - The ownership percentages of concerted parties, other non-public shareholders, and public shareholders have been adjusted as a result of the share issuance [1] - The net proceeds from the offerings are intended for research and development plans, market development, strategic investments, acquisitions, and to supplement working capital [1]

Core Viewpoint - The company has entered a strategic partnership with Silk Road Technology to localize and promote cognitive impairment digital therapy products in Malaysia and Southeast Asia, aiming to advance the digital health industry in the region [1][2]. Group 1: Market Context - Malaysia is facing challenges due to rapid population aging and increasing mental health needs, with 3.8 million people aged 60 and above as of 2023 [1]. - The country has a significant shortage of mental health resources, with a psychological counseling ratio of 1:52,000, far below the international standard of 1:500, indicating a substantial market gap [1]. Group 2: Company Background - The company is a pioneer in the cognitive impairment digital therapy market in China, with its core product being the first regulatory-approved digital therapy for cognitive impairment, included in the reimbursement catalog of provincial medical insurance in 30 provinces in China [1]. Group 3: Partnership Details - The partnership includes the establishment of a specialized laboratory for cognitive impairment digital therapy in Malaysia, with Silk Road Technology assisting in local approvals and logistics while the company provides technical and research support [3]. - The collaboration will also involve applying for national innovation pilot projects, conducting clinical trials in selected hospitals, and jointly expanding market reach in Malaysia and other Southeast Asian countries like Indonesia, Thailand, and Vietnam [3]. Group 4: Strategic Benefits - This collaboration is expected to create long-term growth opportunities for the company and sustainable value for shareholders by expanding its international presence and leveraging local resources for efficient market entry [4]. - The partnership enhances the company's brand authority and professional image in the digital healthcare sector, facilitating quicker product integration into local medical institutions and broadening its market in digital health management [4].

Core Viewpoint - The company has entered a strategic partnership with Silk Road Technology Co., Ltd. to promote the localization and market development of cognitive impairment digital therapy products in Malaysia and Southeast Asia, addressing the growing mental health needs in the region [1][4]. Group 1: Partnership Details - The collaboration includes the establishment of a specialized laboratory for cognitive impairment digital therapy in Malaysia, with Silk Road assisting in local approvals and logistics while the company provides technical and research support [3]. - Silk Road will lead the application for national innovation pilot projects, facilitating the company's engagement with Malaysian authorities [3]. - The partnership will also focus on clinical pilot projects in hospitals, with Silk Road identifying target hospitals and the company adapting products for local use [3]. - Both parties will work together to expand market presence in Malaysia and other Southeast Asian countries, including Indonesia, Thailand, and Vietnam [3]. Group 2: Market Context and Opportunities - Malaysia is facing challenges related to an aging population and increasing mental health demands, with 3.8 million people aged over 60 in 2023 and a significant shortage of mental health resources [1]. - The company is a pioneer in the cognitive impairment digital therapy market in China, with its core product being the first approved digital therapy for cognitive impairment, already included in the reimbursement catalog of 30 provinces in China [1]. - The partnership is expected to enhance the company's international presence and brand influence, leveraging Silk Road's extensive local resources and networks in Malaysia to accelerate market entry and improve commercial conversion efficiency [4].

Group 1 - The company announced the completion of a placement of 92 million shares at a price of HKD 5.6 per share on January 27, 2026, with at least six independent third-party subscribers [1] - Following the completion of the placement, the company will issue 92 million shares under a subscription agreement at the same price of HKD 5.6 per share on February 5, 2026 [1] - The estimated net proceeds from the placement and subscription, after deducting all related expenses, are approximately HKD 501 million [1]

Group 1 - The company Brainstorm Aurora-B (06681) completed a placement of 92 million shares at a price of HKD 5.6 per share on January 27, 2026, with at least six independent third-party subscribers [1] - Following the completion of the placement, the company will issue 92 million shares under a prior subscription agreement at the same price of HKD 5.6 per share on February 5, 2026 [1] - The estimated net proceeds from the placement and subscription, after deducting all related expenses, are approximately HKD 501 million [1]

Core Viewpoint - The company has entered into a strategic cooperation agreement with Silk Road Technology Co., Ltd. to promote the localization, market promotion, and scientific transformation of cognitive impairment digital therapy products in Malaysia and Southeast Asia [1] Group 1: Strategic Cooperation - The agreement includes the establishment of a specialized laboratory for cognitive impairment digital therapy in Malaysia [1] - Silk Road Technology will assist the company in coordinating local approvals, site planning, and equipment importation [1] - The company will provide technical solutions and research support, leading the research and operational aspects [1]

Core Viewpoint - The company has entered into a strategic cooperation agreement with Silk Road Voyager Technology Co., Ltd. to promote the localization and market development of cognitive impairment digital therapy products in Malaysia and Southeast Asia, aiming to advance the digital health industry [1] Group 1: Cooperation Details - The cooperation includes the establishment of a specialized laboratory for cognitive impairment digital therapy in Malaysia, with Silk Road Voyager assisting in local approvals and logistics while the company provides technical solutions and research support [2] - Silk Road Voyager will lead the application for national innovation pilot projects in Malaysia, facilitating the joint implementation of these projects [2] - The partnership will involve selecting target hospitals for clinical pilot agreements, with the company responsible for product localization, training, and data collection [2] - Both parties will collaborate on market promotion and commercialization in Malaysia by integrating resources such as products, channels, and brands [2] - The cooperation will serve as a foundation for expanding into other Southeast Asian countries like Indonesia, Thailand, and Vietnam [2] Group 2: Long-term Development Opportunities - The collaboration is expected to deepen the company's international presence and expand its overseas market, marking its entry into Malaysia and enhancing its business network in Southeast Asia [3] - By leveraging local resources, the partnership aims to accelerate market entry and improve commercial conversion efficiency through Silk Road Voyager's extensive government and healthcare network in Malaysia [3] - The cooperation will enhance the company's brand authority and professional image in the digital healthcare sector, facilitating faster product integration into local medical institutions and expanding into diverse markets such as digital health management [3]

Core Viewpoint - The company successfully completed a placement of 92 million shares at a price of HKD 5.6 per share, raising approximately HKD 500.68 million for various strategic initiatives [1] Group 1: Placement Details - The placement was completed on January 27, 2026, with shares sold to no less than six subscribers [1] - The shares were issued under the terms of a placement and subscription agreement [1] Group 2: Use of Proceeds - The net proceeds from the placement are intended for several purposes, including funding research and development programs, domestic and international market development, strategic investments and acquisitions, and general working capital for the company and its subsidiaries [1]

BrainAurora Medical Technology Limited 香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 （股份代號：6681） 自願公告 訂立戰略合作協議以拓展馬來西亞市場及深化國際化布局 本公告為腦動極光醫療科技有限公司（「本公司」，連同其附屬公司統稱「本集團」） 自願發布的公告，目的是使廣大投資者了解本集團最新業務發展情況。 本公司董事會（「董事會」）欣然宣布，本公司與絲路之舟科技有限公司（「絲路之 舟」）訂立戰略合作協議（「協議」），雙方將在馬來西亞及東南亞區域圍繞認知障礙 數字療法產品的本土化落地、市場推廣與科研轉化等領域開展深度戰略合作，共 同推動數字健康產業發展。 合作背景與內容 馬來西亞為東南亞重要經濟體之一，正面臨快速人口老化及精神健康需求攀升 的挑戰。根據馬來西亞統計局數據，2023年該國60歲以上人口達380萬。與此同 時，青少年心理健康問題亦日益突出。馬來西亞政府雖已推動多項精神健康政 策，然診療資源仍顯稀 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示，概不對因本公告全部或任何部分內容而產生或因倚 賴該等內容而引致的任何損失承擔任何責任。 本公告僅作參考用途，並不構成收購、購買或認購本公司任何證券的邀請或要約。 BrainAurora Medical Technology Limited 腦動極光醫療科技有限公司 （於開曼群島註冊成立的有限公司） （股份代號：6681） 完成 根據一般授權配售現有股份及先舊後新認購新股份 獨家整體協調人、配售代理及資本市場中介機構 完成配售事項及先舊後新認購事項 董事會欣然宣佈，配售事項已根據配售及認購協議的條款及條件於2026年1月27 日完成，配售代理按盡力基準成功按配售價每股配售股份5.6港元向不少於六(6) 名承配人配售合共92,000,000股配售股份。據董事經作出一切合理查詢後所深 知、盡悉及確信，承配人及其最終實益擁有人均為獨立第三方。 由於完成先舊後新認購事項的所有條件已達成，本公司於2026年2月5日根據配 售及認購協議的條款及條件按每股先舊後新認購股份5.6港元向賣方配發及發行 92, ...